(Q33871980)

29 July 2017

title

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial (English)

1 reference

29 July 2017

1 reference

hepatocellular carcinoma

1 reference

resectable hepatocellular carcinoma

inferred from title

1 reference

1 reference

ORCID Public Data File 2021

author name string

W Y Lau

1 reference

29 July 2017

T W Leung

1 reference

29 July 2017

S K Ho

1 reference

29 July 2017

M Chan

1 reference

29 July 2017

D Machin

1 reference

29 July 2017

J Lau

1 reference

29 July 2017

A T Chan

1 reference

29 July 2017

W Yeo

1 reference

29 July 2017

T S Mok

1 reference

29 July 2017

S C Yu

1 reference

29 July 2017

N W Leung

1 reference

29 July 2017

P J Johnson

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

353

1 reference

29 July 2017

issue

9155

1 reference

29 July 2017

page(s)

797-801

1 reference

Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

The surgical management of primary carcinoma of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Postoperative Recurrence of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Superselective intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Does hepatitis C virus infection contribute to hepatocellular carcinoma in hong kong?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906475-7

7 January 2021

10.1016/S0140-6736(98)06475-7

Identifiers

DOI

1 reference

29 July 2017

1 reference